AB Science Reports Clinical Study Updates
Biotechnology firm AB Science has provided updates on its clinical programs, primarily focusing on the development of masitinib for various disease treatments.
Biotechnology company AB Science has announced the release of updates concerning its ongoing clinical programs. These updates specifically highlight the development of masitinib, a drug candidate being investigated for the treatment of multiple diseases.
The recent announcements detail masitinib's progress in studies targeting conditions such as amyotrophic lateral sclerosis (ALS), prostate cancer, and pancreatic cancer. The company has also released data from studies evaluating masitinib's potential in treating COVID-19 infections and its efficacy in ALS patients.
AB Science is conducting further research into masitinib across various phases, with its development pipeline including several clinical trials. The company has disclosed information regarding interactions with regulatory bodies, including France's National Agency for the Safety of Medicines and Health Products (ANSM).
In addition to its drug development activities, AB Science has issued corporate communications covering topics such as general meetings and financial results. The company remains focused on advancing its pharmaceutical development efforts, aiming to progress the research and potential approval of masitinib for a range of therapeutic applications.